EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study

Dhir Gala, Sameer Rao iD, Manas Gunani iD, Kajol Shah, Anand V Kulkarni iD, Karn Wijarnpreecha, Daniel Q Huang iD, Pojsakorn Danpanichkul iD, Ahmed Al-Khazraji iD, Kaveh Hajifathalian, Vivek Lingiah, Paul Gaglio iD und 2 weitere

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70896 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Dhir Gala und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Liver Cirrhosis, Platelet Aggregation Inhibitors, Coronary Artery Disease. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Coronary artery disease (CAD) is common in cirrhosis patients because of shared risk factors, including metabolic syndrome and alcohol use; however, outcomes after percutaneous coronary intervention (PCI) remain poorly defined.

Aims

To evaluate outcomes after PCI in patients with cirrhosis.

Methods

We conducted a retrospective cohort study using TriNetX US Collaborative Network data from 2015 to 2024. Adults undergoing PCI were stratified by cirrhosis status, with outcomes including gastrointestinal bleeding, ischaemic events, and all‐cause mortality. Within the cirrhosis cohort, we evaluated effect modification by aetiology, disease severity, and antiplatelet strategy at 30 days after PCI. One‐to‐one propensity score matching adjusted for demographics and comorbidities, with results reported as relative risks and 95% confidence intervals.

Results

Among 3351 patients with cirrhosis undergoing PCI matched 1:1 to controls, cirrhosis was associated with higher 1‐year gastrointestinal bleeding (16.14% vs. 8.12%; p < 0.0001) and mortality (13.97% vs. 10.41%; p < 0.0001). Decompensated cirrhosis had higher gastrointestinal bleeding and mortality than compensated disease, while alcohol‐associated cirrhosis had higher gastrointestinal bleeding than metabolic dysfunction‐associated steatotic liver disease (MASLD) cirrhosis. In a 30‐day landmark analysis, antiplatelet monotherapy (aspirin or P2Y12 inhibitors) had lower 1‐year gastrointestinal bleeding (10.31% vs. 20.77%; p < 0.0001) and mortality (9.46% vs. 12.89%; p = 0.04) without increased stent restenosis compared with dual antiplatelet therapy (DAPT).

Conclusion

Cirrhosis confers substantially higher bleeding and mortality after PCI, particularly in decompensated disease. Antiplatelet monotherapy after 30 days was associated with less bleeding and improved survival, supporting abbreviated DAPT in this high‐risk group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionLiver CirrhosisPlatelet Aggregation InhibitorsCoronary Artery DiseaseHumansFemaleMaleRetrospective StudiesAgedGastrointestinal HemorrhageTreatment OutcomeMiddle AgedRisk FactorsUnited States

Stichwörter der Autor:innen

antiplatelet therapycirrhosiscoronary artery diseasepercutaneous coronary intervention

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
  • Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
  • Divison of Cardiology, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
  • Division of Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, India.
  • Division of Gastroenterology and Hepatology, University of Arizona College of Medicine, Phoenix, Arizona, USA.
  • Division of Gastroenterology and Hepatology, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Sameer Rao, Manas Gunani, Anand V Kulkarni, Daniel Q Huang, Pojsakorn Danpanichkul, Ahmed Al-Khazraji, Paul Gaglio

Zitieren

APA

Gala, D., Rao, S., Gunani, M., Shah, K., Kulkarni, A. V., Wijarnpreecha, K., Huang, D. Q., Danpanichkul, P., Al-Khazraji, A., Hajifathalian, K., Lingiah, V., Gaglio, P., Duong, N., & Gerula, C. (2026). Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70896

Vancouver

Gala D, Rao S, Gunani M, Shah K, Kulkarni AV, Wijarnpreecha K, et al. Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70896

BibTeX
@article{Gala2026,
  author = {Gala, Dhir and Rao, Sameer and Gunani, Manas and Shah, Kajol and Kulkarni, Anand V and Wijarnpreecha, Karn and Huang, Daniel Q and Danpanichkul, Pojsakorn and Al-Khazraji, Ahmed and Hajifathalian, Kaveh and Lingiah, Vivek and Gaglio, Paul and Duong, Nikki and Gerula, Christine},
  title = {Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70896}
}
Kostenlos starten →